

## MIRCERA<sup>®</sup> (methoxy polyethylene glycol-epoetin beta) Medication Precertification Request

Page 1 of 2

(All fields must be completed and legible for precertification review.)

 Aetna Precertification Notification

 Phone:
 <u>1-866-752-7021</u> (TTY: <u>711)</u>

 FAX:
 <u>1-888-267-3277</u>

For Medicare Advantage Part B: Please Use Medicare Request Form

| Please indicate:                                | Start of treatment: Start  |  | -   |                        |                                     |                    |  |
|---|--|--|---|------------------------|-------------------------------------|--------------------|--|
|   | Continuation of therapy:   | Date of last treatment   | last treatment ///  |                        | Fam                                 |                    |  |
|   | equested By:   |  | Phone:  |                        | Fax:                                |                    |  |
| A. PATIENT INFO                                 | RMATION  |  |   |                        |                                     |                    |  |
| First Name:                                     |  |  | Last Name:  |                        |                                     |                    |  |
| Address:  |  | 1  | City:   |                        | State:                              | ZIP:               |  |
| Home Phone:                                     |  | Work Phone:  |   | Cell Phone:            |                                     |                    |  |
| DOB:  | Allergies:   |  |   | Email:                 |                                     |                    |  |
| Current Weight:                                 | lbs orI  | kgs Height:  | inches or   | cms                    |                                     |                    |  |
| <b>B. INSURANCE IN</b>                          | FORMATION  |  |   |                        |                                     |                    |  |
| Aetna Member ID                                 | #:   | Does patient have  | Does patient have other coverage?   |                        |                                     |                    |  |
|   |  | -  | If yes, provide ID#: Carrier Name:  |                        |                                     |                    |  |
| Insured:  |  | Insured:   |   |                        |                                     |                    |  |
| Medicare: 🗌 Yes                                 | □ No If yes, provide ID #:   |  | Medicaid: Yes   | No If yes, pro         | vide ID #:                          |                    |  |
| C. PRESCRIBER                                   | INFORMATION  |  |   |                        |                                     |                    |  |
| First Name:                                     |  | Last Name:   |   | (Check On              | e): 🗌 M.D. 🗌                        | D.O. 🗌 N.P. 🗌 P.A. |  |
| Address:  |  |  | City:   |                        | State:                              | ZIP:               |  |
| Phone:  | Fax:   | St Lic #:  | NPI #:  | DEA #:                 | UF                                  | PIN:               |  |
| Provider Email:                                 |  | Office Contact Nar   | ne:   |                        | Phone:                              |                    |  |
| Specialty (Check of                             | one): 🗌 Oncologist 🔲 Ne  | phrologist   |   |                        |                                     |                    |  |
|   | PROVIDER/ADMINISTRATION  |  |   |                        |                                     |                    |  |
| Center Na<br>Home Infusion<br>Agency Na         | ed Physician's Officients of the sion Center Phone:  |  | Dispensing Prov           □ Physician's O           □ Specialty Pha              Address:              Phone:              TIN: | ffice [                | ] Retail Pharma<br>] Other:<br>Fax: | acy                |  |
|   |  |  | I IN  |                        | F IN                                |                    |  |
| E. PRODUCT INF                                  |  |  | Deser   | <b>F</b>               |                                     |                    |  |
|   | RCERA (methoxy polyethyle  |  |   |                        | .y:                                 |                    |  |
|   | FORMATION – Please indicate  |  |   |                        |                                     |                    |  |
| =   |  |  |   |                        |                                     |                    |  |
|   | <b>DRMATION</b> – Required clinical  |  | pleted in its <u>entirety</u> for a   | Il precertification    | requests.                           |                    |  |
| Yes No Doe                                      | (clinical documentation require<br>es the patient have a documente<br>I the requested drug be used cor   | d diagnosis of anemia due to   |   |                        |                                     |                    |  |
|   | s the patient received erythropoie   |  | therapy in the previous m   | onth (within 30 d      | ays of request)?                    | 1                  |  |
|   | ests (clinical documentation re  |  |   |                        |                                     |                    |  |
| Yes No Doe<br>Yes No Has<br>Please indicate the | es the patient have a contraindica<br>es the patient have a contraindica<br>s the patient been assessed for in<br>patient's most recent serum tran<br>he patient receiving iron therapy? | ation, intolerance or ineffecti<br>ron deficiency anemia?<br>sferrin saturation (TSAT) lev | ve response to Aranesp?   | <u>%</u> Date of test: | /                                   |                    |  |
| Please indicate the                             | patient's pretreatment hemoglob  | in (Hgb) level (exclude value  | es due to a recent transfus   | sion):                 | Date of test:                       | 1 1                |  |

Continued on next page



## MIRCERA® (methoxy polyethylene glycol-epoetin beta) Medication Precertification Request

Page 2 of 2

 Aetna Precertification Notification

 Phone:
 <u>1-866-752-7021</u> (TTY: <u>711)</u>

 FAX:
 <u>1-888-267-3277</u>

For Medicare Advantage Part B: Please Use Medicare Request Form

(All fields must be completed and legible for precertification review.)

| Patient First Name  | Patient Last Name | Patient Phone | Patient DOB |  |  |  |  |  |
|---|-------------------|---------------|-------------|--|--|--|--|--|
|   |                   |               |             |  |  |  |  |  |
| G. CLINICAL INFORMATION (continued) – Required clinical information must be completed in its entirety for all precertification requests.  |                   |               |             |  |  |  |  |  |
| For Continuation Requests (clinical documentation required for all requests):   |                   |               |             |  |  |  |  |  |
| Yes       No       Has the patient completed at least 12 weeks of erythropoiesis stimulating agent (ESA) therapy?         Please indicate the number of weeks completed:  |                   |               |             |  |  |  |  |  |
| Date of test: / /   |                   |               |             |  |  |  |  |  |
| H. ACKNOWLEDGEMENT  |                   |               |             |  |  |  |  |  |
| Request Completed By (Signature Required  | ı):               |               | Date: / /   |  |  |  |  |  |
| Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties. |                   |               |             |  |  |  |  |  |

The plan may request additional information or clarification, if needed, to evaluate requests.